Handbook of Pharmaceutical Public Policy - Rilegato

Rilegato

ISBN 10: 0789030586 ISBN 13: 9780789030580

Casa editrice: CRC Press, 2007

Riassunto

Get an invaluable view of the impact of economics and politics on pharmaceuticals in the United States

Pharmacy and pharmaceutical drug use are highly regulated and the various regulatory forces interact with diverse goals. Pharmaceutical Public Policy is a comprehensive review of the legislation, trends, business developments, and policy interpretations that have shaped drug use during the last 50 years. This unique single source explains drug regulatory activity, the major insurance and payment systems, and the impact of economics and politics on drug use in the United States. Leading experts provide a thorough and objective look at public policy issues, making this text perfect for upper level undergraduate and graduate level pharmacy, medical, and public health educators and students.

Pharmacists and pharmacy students must learn more than just the physical sciences and clinical aspects of the pharmaceutical industry. The rationale for policies, rules, and regulations is integral to understanding how to best serve patients and make the entire pharmaceutical sector more equitable and cost-effective. Pharmaceutical Public Policy examines the most pressing issues facing the industry, including control of the rising costs for drugs and ensuring correct drug usage by patients. This insightful text offers an in depth perspective of the policies and the debates that surround them. Chapters are well-referenced and many include helpful figures and tables to illustrate facts and ideas.

Topics in Pharmaceutical Public Policy include:

• pharmacy law and regulation
  
• Medicare and prescription drug coverage
  
• FDA drug approval process
  
• Medicaid and prescription drugs
  
• public health pharmacy
  
• Department of Veterans Affairs pharmacy programs
  
• Department of Defense pharmacy programs
  
• innovative state drug program practices
  
• state and federal regulation of pharmacy
  
• the future of the pharmaceutical industry
  
• managed care pharmacy
  
• PBM’s (pharmacy benefit managers)
  
• risk minimization
  
• importation and reimportation
  
• biotechnology and pharmacogenetics policy and issues
  
• product promotion
  
• competition between drugs
  
• drug insurance design
  
• patient compliance
  
• abuse of prescription drugs
  
• health care systems and insurance in Europe
  
• much more
  
  

Pharmaceutical Public Policy is a one-of-a-kind resource that explains just who the players are and the complexity of the issues that are examined in most pharmaceutical policy debates, and is perfect for pharmacy students, educators, other health professionals, trade association leaders, and policymakers.

Su questo libro

Contenuti:

• About the Editors
• Contributors
• Foreword (Hans V. Hogerzeil)
• Preface
• Chapter 1. Policy, Law, and Regulation (Susan Winckler)
• Chapter 2. The Political Evolution of Medicare and Prescription Drug Coverage (Thomas R. Oliver, Philip R. Lee, Sarah B. Schulman, Susan P. Canny, and Helene L. Lipton)
• Chapter 3. Evolution of the FDA Drug Approval Process (Syed Rizwanuddin Ahmad)
• Chapter 4. The Market for Pharmaceuticals: The Big Picture (David H. Kreling)
• Chapter 5. Medicare’s Prescription Drug Benefit (David J. Gross)
• Chapter 6. Prescription Drugs Under Medicaid (Linda Elam)
• Chapter 7. Public Health Pharmacy (Theodore P. Chiappelli)
• Chapter 8. Department of Veterans Affairs Pharmacy Programs (Michael A. Valentino and Jonathan B. Perlin)
• Chapter 9. The Department of Defense Pharmacy Programs (W. Mike Heath)
• Chapter 10. Outside the Pill Box: Innovative State Prescription Drug Program Practices (Brendan Krause and Kimberly Fox)
• Chapter 11. State versus Federal Regulation of Pharmacy (Melissa Madigan and Ed Rickert)
• Chapter 12. Evolution and Future Prospects of Pharmaceutical Industry Regulation (William Wardell, William Vodra, Judith K. Jones, and Richard N. Spivey)
• Chapter 13. Managed Care Pharmacy: The Past and Present (John D. Jones)
• Chapter 14. Pharmaceutical Benefit Managers (Kimberly P. McDonough)
• Chapter 15. Risk Minimization: A New Regulatory Directive (Louis A. Morris and Eva Lydick)
• Chapter 16. Drug Importation and Reimportation (Albert I. Wertheimer and Thomas Santella)
• Chapter 17. Structure and Dynamics of the Pharmaceutical Industry (Earlene Lipowski and Patrick McKercher)
• Chapter 18. Health Policy and Economic Issues in Biotechnology and Pharmacogenetics (Louis P. Garrison, Jr.)
• Chapter 19. Promoting Pharmaceutical Products (Alan Lyles)
• Chapter 20. Competition: Brand-Name versus Generic Drugs (Jeff J. Guo and Christina M.L. Kelton)
• Chapter 21. Drug Insurance Design (Earle “Buddy” Lingle)
• Chapter 22. Evidence Based Preferred Drug Lists (John Santa)
• Chapter 23. Recent Developments in the Health Technology Assessment Process (Paul C. Langley)
• Chapter 24. Why Is Medication Use Less Than Appropriate? (David P. Nau and Duane Kirking)
• Chapter 25. Diversion, Abuse, and Other Nonmedical Use of Prescription Drugs (Bonnie B. Wilford and Robert L. Dupont)
• Chapter 26. Drug Utilization Review: Dealing with Complexity (Thomas R Fulda and Theodore M Collins)
• Chapter 27. Pharmaceutical Care and Payment for Medication Management Services (Dale B. Christensen)
• Chapter 28. Patient Compliance (Jon C. Schommer and Reshmi L. Singh)
• Chapter 29. Electronic Technology (Gordon Schiff and Bill G. Felkey)
• Chapter 30. Health Care Systems and Health Insurance from a European Perspective (Marion Schaefer and Katja Borchardt)
• Index
• Reference Notes Included

Product Description:

Book by None

Su questa edizione

• Editore: CRC Press
• Data di pubblicazione: 2007
• ISBN 10: 0789030586
• ISBN 13: 9780789030580
• Rilegatura: Copertina rigida
• Numero edizione: 1
• Numero di pagine: 681
• Redattore: Fulda Thomas